Melior Discovery News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Melior discovery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Melior Discovery Today - Breaking & Trending Today

Adhera Therapeutics (ATRX) Announces Management Changes, Plans for NASDAQ Uplist

Adhera Therapeutics (ATRX) Announces Management Changes, Plans for NASDAQ Uplist
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Andrew Kucharchuk , Andrew Al Kucharchuk , Exchange Commission , Corporate Development , Adhera Therapeutics Inc , Company Board Of Directors The , Dupont Pharmaceuticals , Wall Street , Zahed Subhan Phd , Chief Executive Officer , Adhera Therapeutics , Company Director , Chief Operating Officer , Melior Discovery , Non Alcoholic Steatohepatitis , Familial Adenomatous Polyposis , Private Securities Litigation Reform Act , Adhera Therapeutic , Andrew Kucharchuk Chief Executive Officer ,

Adhera Therapeutics Appoints T - GuruFocus.com

GuruFocus Article or News written by GuruFocusNews and the topic is about: ....

Zahed Subhan , Trondk Waerness , Andrew Kucharchuk , Rx Sample Solutions , Company Board Of Directors , Adhera Therapeutics Inc , Royal Norwegian Army , Lundy Fetterman School Of Business At Campbell University , Exchange Commission , Baton Rouge , Cornerstone Biopharma , Jobson Healthcare , Lundy Fetterman School , Chief Executive Officer , Chief Scientific , Melior Discovery , Non Alcoholic Steatohepatitis , Familial Adenomatous Polyposis , Private Securities Litigation Reform Act , Adhera Therapeutic , Adhera Therapeutics ,

Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ

Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Zahed Subhan , Trondk Waerness , Andrew Kucharchuk , Rx Sample Solutions , Company Board Of Directors , Adhera Therapeutics Inc , Royal Norwegian Army , Lundy Fetterman School Of Business At Campbell University , Exchange Commission , Cornerstone Biopharma , Jobson Healthcare , Lundy Fetterman School , Chief Executive Officer , Chief Scientific , Melior Discovery , Non Alcoholic Steatohepatitis , Familial Adenomatous Polyposis , Private Securities Litigation Reform Act , Adhera Therapeutic , Adhera Therapeutics , Andrew Kucharchuk Chief Executive Officer ,

Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr.

Baton Rouge, LA, March 21, 2022 (GLOBE NEWSWIRE) Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage. ....

United States , New York , Columbia University , Jean Buteau , Domenico Accili , Marc Prentki , Shastri Indo , Andrew Kucharchuk , Diabete Quebec , University Of Alberta , Laval University , Medicine At Laval University , Company Scientific Advisory Board , Diabetes Research Foundation , Engineering Research Council , Company Phase , Quebec Research Funds , Laval University In Quebec , Adhera Therapeutics Inc , University Of Montreal , Alberta Diabetes Institute , Canada Institute , Canadian Institutes Of Health Research , Exchange Commission , Canada Foundation For Innovation , Canadian Diabetes Association ,

Manufacturing Commences on Adhera's MLR-1019 for Phase 2a Clinical Trial Treating Parkinson's Disease

Baton Rouge, LA, Oct. 15, 2021 (GLOBE NEWSWIRE) — Adhera Therapeutics, Inc. (OTCPK: ATRX) (“Adhera” or the “Company”), a clinical stage biopharmaceutical company, today announces that manufacturing has commenced of MLR-1019 (armesocarb) for use in the Company’s planned Phase 2a clinical trial as a new therapeutic for Parkinson’s disease (PD). Adhera is also pleased to inform shareholders that a new patent has been issued covering MLR-1019 in Korea. Adhera is actively working to initiate a Phase 2a study designed to be a multi-center, double blind, randomized, placebo controlled clinical trial conducted in Eastern Europe to evaluate MLR-1019 as the only PD product under development that will address both movement and non-movement aspects of the disease. To the best of the Company’s knowledge, all existing agents that treat movement disorder, exacerbate non-movement disorder features of PD. Enrollment in the Phase 2 trial is expected to consist of Park ....

New Zealand , Hong Kong , South Africa , South Korea , Andrew Kucharchuk , Exchange Commission , Korean Intellectual Property Office , Melior Pharmaceuticals , Europe Union , Adhera Therapeutics Inc , Baton Rouge , Adhera Therapeutics , Eastern Europe , Chief Executive Officer , Eastern European , Investigational New Drug , Korean Patent , Melior Discovery , Familial Adenomatous Polyposis , Private Securities Litigation Reform Act , License Agreement , Adhera Therapeutic ,